Oramed Pharmaceuticals Inc.
Hedge Funds Holdings
Last updated:
Oramed Pharmaceuticals Inc.‘s stocks are currently a part of 64 hedge funds’ portfolios, which represents 9.78% of the total amount of its stocks outstanding. This makes up a total of 3.79M shares of Oramed Pharmaceuticals Inc.. Compared to the previous quarter, the number fell by -43.26% or -2.89M shares fewer. As for the holding position changes, 32.81% (21) of current hedge fund investors increased the number of shares held, 34.38% (22) of current holders sold a part of the shares held, and 23.44% (15) closed the holdings completely. 3 hedge funds are new holders of Oramed Pharmaceuticals Inc. stock in Q3 2022, it is 4.69% of total holders.
Hedge funds holding Oramed Pharmaceuticals (Q4 2017 – Q3 2022)
| Q4 2017 | 27 |
|---|---|
| Q1 2018 | 21 |
| Q2 2018 | 21 |
| Q3 2018 | 28 |
| Q4 2018 | 28 |
| Q1 2019 | 25 |
| Q2 2019 | 26 |
| Q3 2019 | 29 |
| Q4 2019 | 30 |
| Q1 2020 | 31 |
| Q2 2020 | 32 |
| Q3 2020 | 34 |
| Q4 2020 | 39 |
| Q1 2021 | 44 |
| Q2 2021 | 75 |
| Q3 2021 | 92 |
| Q4 2021 | 115 |
| Q1 2022 | 101 |
| Q2 2022 | 86 |
| Q3 2022 | 64 |
Hedge funds changes in Oramed Pharmaceuticals positions (Q4 2017 – Q3 2022)
| Q4 2017 | 6 | 9 | 3 | 1 | 8 |
|---|---|---|---|---|---|
| Q1 2018 | 2 | 2 | 5 | 8 | 4 |
| Q2 2018 | 3 | 2 | 4 | 3 | 9 |
| Q3 2018 | 8 | 5 | 4 | 1 | 10 |
| Q4 2018 | 4 | 6 | 5 | 4 | 9 |
| Q1 2019 | 3 | 5 | 3 | 6 | 8 |
| Q2 2019 | 4 | 4 | 5 | 3 | 10 |
| Q3 2019 | 5 | 5 | 4 | 2 | 13 |
| Q4 2019 | 6 | 3 | 10 | 5 | 6 |
| Q1 2020 | 8 | 6 | 7 | 4 | 6 |
| Q2 2020 | 6 | 8 | 3 | 6 | 9 |
| Q3 2020 | 6 | 10 | 5 | 4 | 9 |
| Q4 2020 | 13 | 5 | 9 | 8 | 4 |
| Q1 2021 | 13 | 17 | 4 | 8 | 2 |
| Q2 2021 | 39 | 17 | 8 | 8 | 3 |
| Q3 2021 | 26 | 39 | 13 | 9 | 5 |
| Q4 2021 | 36 | 43 | 15 | 13 | 8 |
| Q1 2022 | 12 | 33 | 28 | 25 | 3 |
| Q2 2022 | 20 | 25 | 16 | 34 | -9 |
| Q3 2022 | 3 | 21 | 22 | 15 | 3 |
Hedge funds changes in Oramed Pharmaceuticals stock options (Q4 2017 – Q3 2022)
| Q4 2017 | 0 | 28,000 |
|---|---|---|
| Q1 2018 | 0 | 20,000 |
| Q2 2018 | 0 | 23,000 |
| Q3 2018 | 0 | 4,000 |
| Q4 2018 | 0 | 3,000 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 1,000 |
| Q3 2019 | 0 | 48,000 |
| Q4 2019 | 561,000 | 1,061,000 |
| Q1 2020 | 378,000 | 550,000 |
| Q2 2020 | 345,000 | 335,000 |
| Q3 2020 | 61,000 | 0 |
| Q4 2020 | 304,000 | 493,000 |
| Q1 2021 | 2,116,000 | 2,393,000 |
| Q2 2021 | 3,129,000 | 2,912,000 |
| Q3 2021 | 8,933,000 | 6,129,000 |
| Q4 2021 | 4,691,000 | 2,517,000 |
| Q1 2022 | 1,764,000 | 928,000 |
| Q2 2022 | 572,000 | 228,000 |
| Q3 2022 | 695,000 | 605,000 |